Quick Answer
Hepion Pharmaceuticals, Inc. reported Cash and Equivalents of $13.92 million for fiscal year 2019.
Hepion Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2019 | $13.92M | +391.6% |
| 2018 | $2.83M | -52.4% |
| 2017 | $5.95M | -54.1% |
| 2017 | $12.98M | +75.3% |
| 2016 | $7.40M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2019 | $14.86M | +64.6% | -13.3% |
| June 30, 2019 | $17.15M | +564.6% | +919.2% |
| March 31, 2019 | $1.68M | -57.9% | -40.6% |
| December 31, 2018 | $2.83M | -52.4% | -68.6% |
| September 30, 2018 | $9.03M | — | +250.0% |
| June 30, 2018 | $2.58M | — | -35.5% |
| March 31, 2018 | $4.00M | — | -32.9% |
| December 31, 2017 | $5.95M | — | — |
- Hepion Pharmaceuticals, Inc. showed an increase of +391.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2019 period, Hepion Pharmaceuticals, Inc.’s cash and equivalents has grown by 88.0% (from $7.40 million to $13.92 million).
- The most recent figure is from Hepion Pharmaceuticals, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on May 14, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: